NCT04444700View on ClinicalTrials.gov

A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic

PHASE3CompletedINTERVENTIONAL
Enrollment

465

Participants

Timeline

Start Date

July 4, 2020

Primary Completion Date

May 10, 2021

Study Completion Date

October 14, 2021

Conditions
COVIDCoronavirus InfectionSevere Acute Respiratory SyndromeThromboembolism, VenousAnticoagulants and Bleeding Disorders
Interventions
DRUG

Therapeutic anticoagulation

The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.

Trial Locations (1)

05402-000

Hospital das Clínicas da FMUSP, São Paulo

All Listed Sponsors
collaborator

Unity Health Toronto

OTHER

collaborator

University of Vermont Medical Center

OTHER

lead

University of Sao Paulo General Hospital

OTHER

NCT04444700 - A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic | Biotech Hunter | Biotech Hunter